This study was designed as a random , double-blinded , placebo controlled clinical trial in 66 centers in China and was conducted from may , 1996 to December , 2003.4870 CHD patients ( serum cholesterol level 4.40 - 6.47 mmol/L , age 18 - 75 years , with definite myocardial infarction history ) were selected and treated with capsule Xuezhikang ( 0.6 g Bid ) or placebo in addition to conventional therapy ( control group ) .
